This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Zurampic
  • /
  • Combination Treatment Study in Subjects With Topha...
Clinical trial

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat (CRYSTAL)

Read time: 3 mins
Last updated:1st Jan 2012
Identifier: NCT01510769
This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with febuxostat to febuxostat alone in patients with tophaceaous gout.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects With Tophaceous Gout
Enrollment: 330
Study Start Date: January 2012
Study Completion Date: June 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
lesinurad 400 mg + febuxostat 80 mg
- Experimental: lesinurad 200 mg + febuxostat 80 mg
- Placebo Comparator: placebo + febuxostat 80 mg


Related Journal: Lesinurad: A Review in Hyperuricaemia of Gout.

Category Value
Date last updated at source 2016-04-10
Study type(s) Interventional
Expected enrolment 330
Study start date 2012-01-01
Estimated primary completion date 2014-06-01

View full details